Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopenia

William P. Maier, David S. Gordon, Robert F. Howard, Mansoor N. Saleh, Stephen B. Miller, Jefrey D. Lieberman, Pamela M. Woodlee

Research output: Contribution to journalArticlepeer-review

74 Citations (Scopus)


Seven patients with thrombocytopenia and systemic lupus erythematosus were treated with intravenous (IV) doses of human immunoglobulin to assess clinical response and to examine the mechanism of action of IV immunoglobulin in these patients. Five of 7 patients had a >50% increase in their platelet counts. Four of these patients had a sustained benefit of at least 6 months duration. The initial effectiveness of IV immunoglobulin therapy was not dependent on the reduction of levels of circulating platelet‐binding IgG or circulating immune complexes.

Original languageEnglish
Pages (from-to)1233-1239
Number of pages7
JournalArthritis and Rheumatology
Issue number8
Publication statusPublished - Aug 1990
Externally publishedYes


Dive into the research topics of 'Intravenous immunoglobulin therapy in systemic lupus erythematosus‐associated thrombocytopenia'. Together they form a unique fingerprint.

Cite this